Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Finished Goods (2016 - 2025)

Sonoma Pharmaceuticals has reported Finished Goods over the past 13 years, most recently at $2.0 million for Q4 2025.

  • For Q4 2025, Finished Goods fell 2.74% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 2.74%, while the annual FY2025 figure was $1.8 million, 49.88% up from the prior year.
  • Finished Goods for Q4 2025 was $2.0 million at Sonoma Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Over five years, Finished Goods peaked at $2.4 million in Q2 2025 and troughed at $773000.0 in Q3 2021.
  • A 5-year average of $1.4 million and a median of $1.2 million in 2021 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: plummeted 51.87% in 2021 and later surged 91.92% in 2025.
  • Year by year, Finished Goods stood at $1.3 million in 2021, then decreased by 1.12% to $1.2 million in 2022, then increased by 16.96% to $1.4 million in 2023, then soared by 38.54% to $2.0 million in 2024, then fell by 2.74% to $2.0 million in 2025.
  • Business Quant data shows Finished Goods for SNOA at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.4 million in Q2 2025.